Trial intelligence / Profile preview

Pulsatile versus continuous oxytocin for induction of labour

ACTRN12623000238673Phase 4Not yet recruiting

Sponsor
Northern Health
Start
Mar 2023
Modality
Recombinant Proteins and Enzymes, Peptides
Countries
1
01

Overview

Phase 4, randomised, open-label trial of oxytocin (2 arms), sponsored by Northern Health. Primary endpoint: Duration of labour. Planned start Mar 2023; status: not yet recruiting.

02

Drugs

oxytocin

Beyond the preview

Go deeper on ACTRN12623000238673.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ACTRN12623000238673.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call